采购主管-物料组
广州燃石医学检验所有限公司
- 公司规模:1000-5000人
- 公司性质:民营公司
- 公司行业:制药/生物工程
职位信息
- 发布日期:2020-08-20
- 工作地点:广州-海珠区
- 招聘人数:1人
- 工作经验:3-4年经验
- 学历要求:本科
- 职位月薪:0.8-1.2万/月
- 职位类别:采购主管
职位描述
主要职责:
1.负责运营所需的物料采购工作:包括但不限于供应商寻源、比价、招标、制定采购策略、签定采购合同等工作;
2.供应商开发和管理:负责供应商寻源开发、资质审查;供应商信息的维护和更新,定期进行评估、考核,开发具有竞争力的供应商;
3.采购实施:根据釆购需求制定采购策略和计划,组织商务谈判,控制采购成本,进行有效的内外沟通保证顺利实施;采购标的交付及验收跟进;质量及售后问题处理;
4.负责组别采购流程的优化和完善;
5.完成领导交代的其他工作。
资历要求:
1.5年或以上医疗、制药、贸易、设备相关及相关行业采购工作经验,相关医疗器械、药品行业的采购工作经验者为优;
2.有较强的工作组织能力和管理经验;
3.熟悉采购流程,熟悉供应商审核和供应链管理技巧;具备一定的谈判技巧;熟悉合同法和合同条款;
4.具备良好的表达能力、沟通协调能力和出色的谈判能力;
5.思维反应敏捷,为人热情坦诚;
6.强烈的成本意识,能在压力下工作;
7.具备良好的职业道德及从业人员操守,较强的沟通能力及团队合作精神。
教育背景要求:
1.本科以上毕业,工商管理、供应链管理、物流、药学、等相关专业优先。
职业经验:
1.有医疗器械行业的原辅料采购经验;
2.供应商开发、现场审计等供应商管理经验;
3.曾成功主导供应商的谈判工作;
4.医疗器械或者IVD相关法律法规。
公司介绍
关于燃石医学
燃石医学(纳斯达克代码:BNR)成立于2014年,公司使命为“用科学守护生命之光”,专注于为肿瘤精准医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖:1)基于NGS的肿瘤患病人群检测,6年间,燃石累计检测样本超过18.5万例,在中国市场份额领跑行业;2)基于NGS的癌症早检,目前已经进入临床验证阶段。
燃石医学于2018年7月率先获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒,在体外诊断领域具有里程碑式意义。实验室获得广东省临检中心颁发的 “高通量测序实验室”技术审核,以及得美国CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准医疗领域的发展。
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology.
燃石医学(纳斯达克代码:BNR)成立于2014年,公司使命为“用科学守护生命之光”,专注于为肿瘤精准医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖:1)基于NGS的肿瘤患病人群检测,6年间,燃石累计检测样本超过18.5万例,在中国市场份额领跑行业;2)基于NGS的癌症早检,目前已经进入临床验证阶段。
燃石医学于2018年7月率先获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒,在体外诊断领域具有里程碑式意义。实验室获得广东省临检中心颁发的 “高通量测序实验室”技术审核,以及得美国CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准医疗领域的发展。
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology.
联系方式
- Email:simin.huang@brbiotech.com
- 公司地址:广州国际生物岛星岛环北路5号(燃石医学)
- 电话:17710099363